EYPT · EyePoint, Inc. · Insider Trading

On August 20, 2026, the reporting person transferred owned shares of Common Stock of the Company from an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

These securities are held in a trust for the benefit of the reporting person's children. JP Morgan Trust Company of Delaware is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

On August 20, 2026, the reporting person transferred owned shares of Common Stock of the Company to the GEORGE O. ELSTON 2026 GRAT (the "GRAT"), a grantor-retained annuity trust, to which the reporting person is a grantor, trustee and beneficiary.

Includes 779 shares acquired on July 31, 2026, pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

On August 20, 2026, the reporting person transferred owned shares of Common Stock of the Company from an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

On August 20, 2026, the reporting person transferred owned shares of Common Stock of the Company to the GEORGE O. ELSTON 2026 GRAT (the "GRAT"), a grantor-retained annuity trust, to which the reporting person is a grantor, trustee and beneficiary.

These securities are held in the GRAT, a grantor-retained annuity trust, to which the reporting person is a grantor, trustee and beneficiary.

No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

The restricted stock units vested in three ratable annual installments beginning July 10, 2024.

The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.06. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The restricted stock units vest in three ratable annual installments beginning May 25, 2024.

No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

The option to purchase vests and become exercisable as follows: 25% vested at January 3, 2026 and the remainder vests ratably, on a monthly basis, over the remaining three years.

On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the sale, the portion of the option that was sold to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028.

These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

At the time of the sale, the portion of the options sold to the Family Trust and the remaining portion of the option retained by the reporting person was vested in full.

On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the sale, the portion of the option that was sold to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028.

On March 23, 2026, the reporting person sold owned shares of ("Shares") and options to purchase ("Options") Common Stock of EyePoint, Inc. (the "Company") to the Duker Family 2024 Irrevocable Trust, (the "Family Trust"), in exchange for a promissory note in the principal amount of $2,398,220.93, representing the fair market value of the Shares and Options. For Shares, the fair market value was determined by utilizing the average of the high and low per share trading price on the date of the sale. For Options, the fair market value was determined using a Black Scholes model. The securities held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

At the time of the sale, the portion of the options sold to the Family Trust and the remaining portion of the option retained by the reporting person was vested in full.

These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.22 to $18.45. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

On March 2, 2026, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

Includes 966 shares acquired on January 30, 2026, pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

On March 2, 2026, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

These securities are held in a trust for the benefit of the reporting person's children. JP Morgan Trust Company of Delaware is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

The restricted stock units vest in three ratable annual installments beginning January 6, 2024.

The restricted stock units vest in three ratable annual installments beginning January 6, 2024.

The restricted stock units vest in three ratable annual installments beginning January 6, 2024.

No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

The restricted stock units vest in three ratable annual installments beginning January 5, 2025.

No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

The restricted stock units vest in three ratable annual installments beginning January 5, 2025.